Virax Biolabs Valuation
| VRAX Stock | USD 2.01 0.07 3.61% |
Based on Macroaxis valuation methodology, the company appears to be undervalued. Virax Biolabs Group has a current Real Value of $6.49 per share. The regular price of the company is $2.01. Our model measures the value of Virax Biolabs Group from inspecting the company fundamentals such as Shares Owned By Insiders of 7.06 %, return on equity of -0.96, and Current Valuation of 5.36 M as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Virax Biolabs' valuation include:
Price Book 1.6262 | Enterprise Value 5.4 M | Enterprise Value Ebitda 0.4228 | Price Sales 55.7946 | Enterprise Value Revenue 34.2822 |
Undervalued
Today
Please note that Virax Biolabs' price fluctuation is risky at this time. Calculation of the real value of Virax Biolabs Group is based on 3 months time horizon. Increasing Virax Biolabs' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Virax Biolabs is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Virax Stock. However, Virax Biolabs' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 2.01 | Real 6.49 | Target 20.0 | Hype 2.03 | Naive 1.89 |
The intrinsic value of Virax Biolabs' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Virax Biolabs' stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Virax Biolabs Group helps investors to forecast how Virax stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Virax Biolabs more accurately as focusing exclusively on Virax Biolabs' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Virax Biolabs' intrinsic value based on its ongoing forecasts of Virax Biolabs' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Virax Biolabs' closest peers.
Virax Biolabs Cash |
|
Virax Valuation Trend
Analysing the historical paterns of Virax Biolabs' enterprise value and its market capitalization is a good way to estimate and gauge the value of Virax Biolabs Group over time and is usually enough for investors to make rational market timing decisions.
Virax Biolabs Total Value Analysis
Virax Biolabs Group is at this time forecasted to have valuation of 5.36 M with market capitalization of 8.73 M, debt of 224.3 K, and cash on hands of 21.76 K. Please note that valuation may be misleading and is a subject to auditing or accounting errors. We encourage investors to vigilantly validate all of the Virax Biolabs fundamentals before making equity appraisal based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
5.36 M | 8.73 M | 224.3 K | 21.76 K |
Virax Biolabs Investor Information
The company has Price to Book (P/B) ratio of 1.63. Historically many companies with similar price-to-book (P/B) ratio do better than the market in the long run. Virax Biolabs Group recorded a loss per share of 3.36. The entity had not issued any dividends in recent years. The firm had 1:10 split on the 18th of December 2023. Based on the key indicators related to Virax Biolabs' liquidity, profitability, solvency, and operating efficiency, Virax Biolabs Group is not in a good financial situation at this time. It has a very high odds of going through financial crisis in December.Virax Biolabs Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Virax Biolabs has an asset utilization ratio of 2.85 percent. This suggests that the Company is making $0.0285 for each dollar of assets. An increasing asset utilization means that Virax Biolabs Group is more efficient with each dollar of assets it utilizes for everyday operations.Virax Biolabs Ownership Allocation
Virax Biolabs Group has 7.06 % of its outstanding shares held by insiders and 5.37 % owned by institutional holders.Virax Biolabs Profitability Analysis
The company reported the previous year's revenue of 156.42 K. Net Loss for the year was (6.74 M) with loss before overhead, payroll, taxes, and interest of (1.36 K).About Virax Biolabs Valuation
Our relative valuation model uses a comparative analysis of Virax Biolabs. We calculate exposure to Virax Biolabs's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Virax Biolabs's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | 50.6 K | 53.1 K | |
| Pretax Profit Margin | (43.08) | (45.24) | |
| Operating Profit Margin | (41.53) | (43.61) | |
| Net Loss | (43.05) | (45.20) | |
| Gross Profit Margin | 0.32 | 0.34 |
Virax Biolabs Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 2 M |
Virax Biolabs Current Valuation Indicators
Valuation refers to the process of determining the present value of Virax Biolabs Group and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Virax we look at many different elements of the entity such as Virax's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Virax Biolabs, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Virax Biolabs' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Virax Biolabs' worth.Additional Tools for Virax Stock Analysis
When running Virax Biolabs' price analysis, check to measure Virax Biolabs' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Virax Biolabs is operating at the current time. Most of Virax Biolabs' value examination focuses on studying past and present price action to predict the probability of Virax Biolabs' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Virax Biolabs' price. Additionally, you may evaluate how the addition of Virax Biolabs to your portfolios can decrease your overall portfolio volatility.